UNIVERSAL HEALTH REALTY INCOME TRUST Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)

[ad_1]

The following Management's Discussion and Analysis of Financial Condition and
Results of Operations ("MD&A") is intended to promote an understanding of our
operating results and financial condition. The MD&A is provided as a supplement
to, and should be read in conjunction with, our consolidated financial
statements and the accompanying Notes to the Consolidated Financial Statements,
as included in this Annual Report on Form 10-K. The MD&A contains
forward-looking statements that involve risks, uncertainties, and
assumptions. Actual results may differ materially from those anticipated in
these forward-looking statements as a result of various factors, including, but
not limited to, those presented under Item 1A. Risk Factors, and below in
Forward-Looking Statements and Risk Factors and as included elsewhere in this
Annual Report on Form 10-K. This section generally discusses our results of
operations for the year ended December 31, 2021 as compared to the year ended
December 31, 2020. For discussion of our result of operations and changes in our
financial condition for the year ended December 31, 2020 as compared to the year
ended December 31, 2019, please refer to Part II, Management's Discussion and
Analysis of Financial Condition and Results of Operations in our Annual Report
on Form 10-K for the year ended December 31, 2020, as filed with the Securities
and Exchange Commission on February 25, 2021.


Overview


We are a real estate investment trust ("REIT") that commenced operations in
1986. We invest in healthcare and human service related facilities currently
including acute care hospitals, behavioral health care hospitals, specialty
facilities, free-standing emergency departments, childcare centers and
medical/office buildings. As of February 24, 2022, we have seventy-five real
estate investments or commitments in twenty-one states consisting of:

• six hospital facilities consisting of three acute care hospitals and three

        behavioral health care;


  • four free-standing emergency departments ("FEDs");


    •   fifty-eight medical/office buildings, including four owned by
        unconsolidated LLCs/LPs;


  • four preschool and childcare centers, and;


  • three specialty facilities that are currently vacant.

Forward Looking Statements


This report contains "forward-looking statements" that reflect our current
estimates, expectations and projections about our future results, performance,
prospects and opportunities. Forward-looking statements include, among other
things, information concerning our possible future results of operations,
business and growth strategies, financing plans, expectations that regulatory
developments or other matters will not have a material adverse effect on our
business or financial condition, our competitive position and the effects of
competition, the projected growth of the industry in which we operate, and the
benefits and synergies to be obtained from our completed and any future
acquisitions, and statements of our goals and objectives, and other similar
expressions concerning matters that are not historical facts. Words such as
"may," "will," "should," "could," "would," "predicts," "potential," "continue,"
"expects," "anticipates," "future," "intends," "plans," "believes," "estimates,"
"appears," "projects" and similar expressions, as well as statements in future
tense, identify forward-looking statements.

Forward-looking statements should not be read as a guarantee of future
performance or results, and will not necessarily be accurate indications of the
times at, or by which, such performance or results will be achieved.
Forward-looking information is based on information available at the time and/or
our good faith belief with respect to future events, and is subject to risks and
uncertainties that could cause actual performance or results to differ
materially from those expressed in the statements. Such factors include, among
other things, the following:

• Future operations and financial results of our tenants, and in turn ours,

will likely be materially impacted by numerous factors and future

developments related to COVID-19. Such factors and developments include, but

are not limited to, the length of time and severity of the spread of the

pandemic; the volume of cancelled or rescheduled elective procedures and the

volume of COVID-19 patients treated by the operators of our hospitals and

other healthcare facilities; measures our tenants are taking to respond to

      the COVID-19 pandemic; the impact of government and administrative
      regulation, including travel bans and restrictions, shelter-in-place or
      stay-at-home orders, quarantines, the promotion of social distancing,
      business shutdowns and limitations on business activity; vaccine

requirements; changes in patient volumes at our tenants’ hospitals and other

healthcare facilities due to patients’ general concerns related to the risk

of contracting COVID-19 from interacting with the healthcare system; the

impact of stimulus on the health care industry and our tenants; changes in

patient volumes and payer mix caused by deteriorating macroeconomic

conditions (including increases in uninsured and underinsured patients as

the result of business closings and layoffs); potential disruptions to

clinical staffing and shortages and disruptions related to supplies required

      for our tenants' employees and patients, including equipment,
      pharmaceuticals and medical supplies,




                                       33
--------------------------------------------------------------------------------

particularly personal protective equipment, or PPE; potential increases to

expenses incurred by our tenants related to staffing, supply chain or other

expenditures; the impact of our indebtedness and the ability to refinance

such indebtedness on acceptable terms; disruptions in the financial markets

and the business of financial institutions as the result of the COVID-19

pandemic which could impact our ability to access capital or increase

associated borrowing costs; and changes in general economic conditions

nationally and regionally in the markets our properties are located

resulting from the COVID-19 pandemic, including higher sustained rates of

unemployment and underemployment levels and reduced consumer spending and

confidence. There may be significant declines in future bonus rental revenue

earned on the hospital property leased to a subsidiary of UHS to the extent

that the hospital continues to experience significant declines in patient

volumes and revenues. These factors may result in the inability or

unwillingness on the part of some of our tenants to make timely payment of

their rent to us at current levels or to seek to amend or terminate their

leases which, in turn, would have an adverse effect on our occupancy levels

      and our revenue and cash flow and the value of our properties, and
      potentially, our ability to maintain our dividend at current levels.



   •  Due to COVID-19 restrictions and its impact on the economy, we may

experience a decrease in prospective tenants which could unfavorably impact

the volume of new leases, as well as the renewal rate of existing leases.

The COVID-19 pandemic may delay our construction projects which could result

in increased costs and delay the timing of opening and rental payments from

those projects, although no such delays have yet occurred. The COVID-19

pandemic could also impact our indebtedness and the ability to refinance

such indebtedness on acceptable terms, as well as risks associated with

disruptions in the financial markets and the business of financial

institutions as the result of the COVID-19 pandemic which could impact us

from a financing perspective; and changes in general economic conditions

      nationally and regionally in the markets our properties are located
      resulting from the COVID-19 pandemic. COVID-19 has not had a material
      adverse impact on our financial results during 2021. We are not able to

fully quantify the impact that these factors will have on our financial

results during 2022, but developments related to the COVID-19 pandemic are

likely to have a material adverse impact on our future financial results.

• The Centers for Medicare and Medicaid Services (“CMS”) issued an Interim

Final Rule (“IFR”) effective November 5, 2021 mandating COVID-19

vaccinations for all applicable staff at all Medicare and Medicaid certified

facilities. Under the IRS, facilities covered by this regulation must

establish a policy ensuring all eligible staff have received the first dose

      of a two-dose COVID-19 vaccine or a one-dose COVID-19 vaccine prior to
      providing any care, treatment, or other services by December 5, 2021. All

eligible staff must have received the necessary shots to be fully vaccinated

– either two doses of Pfizer or Moderna or one dose of Johnson & Johnson –

by January 4, 2022. The regulation also provides for exemptions based on

recognized medical conditions or religious beliefs, observances, or

practices. Under the IFR, facilities must develop a similar process or plan

for permitting exemptions in alignment with federal law. If facilities fail

      to comply with the IFR by the deadlines established, they are subject to
      potential termination from the Medicare and Medicaid program for
      non-compliance.  In addition, the Occupational Safety and Health

Administration also issued an Emergency Temporary Standard (“ETS”) requiring

all businesses with 100 or more employees to be vaccinated by January 4,

2022. Pursuant to the ETS, those employees not vaccinated by that date will

need to show a negative COVID-19 test weekly and wear a face mask in the

workplace. Legal challenges to these rules ensued, and the U.S. Supreme

Court has upheld a stay of the ETS requirements but permitted the IFR

vaccination requirements to go into effect pending additional litigation.

CMS has indicated that hospitals in states not involved in the Supreme Court

litigation are expected to be in compliance with IFR vaccination

requirements consistent with the dates referenced above. Hospitals in states

that were involved in the Supreme Court litigation must now come into

compliance with first dose requirements by February 13, 2022 and second dose

requirements by March 15, 2022. Hospitals in Texas continue to not be

subject to the IFR, pending the resolution of additional litigation

there. We cannot predict at this time the potential viability or impact of

any such additional litigation on us or the operators of our

facilities. Implementation of these rules could have an impact on staffing

at the operators of our facilities for those employees that are not

vaccinated in accordance with IFR and ETS requirements, and associated loss

of revenues and increased costs resulting from staffing issues could have a

material adverse effect on our financial results or those of the operators.

• Recent legislation, including the Coronavirus Aid, Relief, and Economic

Security Act (the “CARES Act”), the Paycheck Protection Program and Health

Care Enhancement Act (“PPPHCE Act”) and the American Rescue Plan Act of 2021

(“ARPA”), has provided grant funding to hospitals and other healthcare

providers to assist them during the COVID-19 pandemic. There is a high

degree of uncertainty surrounding the implementation of the CARES Act, the

PPPHCE Act and ARPA, and the federal government may consider additional

stimulus and relief efforts, but we are unable to predict whether additional

stimulus measures will be enacted or their impact. There can be no assurance

as to the total amount of financial and other types of assistance our

tenants will receive under the CARES Act, the PPPHCE Act and the ARPA, and

it is difficult to predict the impact of such legislation on our tenants’

operations or how they will affect operations of our tenants’

competitors. There can be no assurance as to whether our tenants would be

required to repay any previously granted funding, due to noncompliance with

      grant terms or otherwise. Moreover, we are unable to assess the extent to
      which anticipated




                                       34
--------------------------------------------------------------------------------

negative impacts on our tenants (and, in turn, us) arising from the COVID-19

pandemic will be offset by amounts or benefits received or to be received

under the CARES Act, the PPPHCE Act and the ARPA.

• A substantial portion of our revenues are dependent upon one operator, UHS,

which comprised approximately 37%, 33% and 31% of our consolidated revenues

for the years ended December 31, 2021, 2020 and 2019, respectively. As

previously disclosed, on December 31, 2021, a wholly-owned subsidiary of UHS

purchased the real estate assets of Inland Valley Campus of Southwest

Healthcare System from us and in exchange, transferred the real estate

assets of Aiken Regional Medical Center and Canyon Creek Behavioral Health

to us. These transactions were approved by the Independent Trustees of our

Board, as well as the UHS Board of Directors. The aggregate annual rental

revenue during 2022 pursuant to the leases for the two facilities

transferred to us is approximately $5.6 million; there is no bonus rent

component applicable to either of these leases. Pursuant to the terms of

the lease on the Inland Valley Campus, we earned $4.5 million of lease

revenue during year ended December 31, 2021 ($2.6 million in base rental and

$1.9 million in bonus rental). Please see Note 4 to the condensed

consolidated financial statements – Lease Accounting, for additional

information related to this asset purchase and sale transaction between us

and UHS.

• We cannot assure you that subsidiaries of UHS will renew the leases on the

hospital facilities and free-standing emergency departments, upon the

scheduled expirations of the existing lease terms. In addition, if

subsidiaries of UHS exercise their options to purchase the respective leased

hospital facilities and FEDs, and do not enter into a substitution

arrangement upon expiration of the lease terms or otherwise, our future

revenues and results of operations could decrease if we were unable to earn

a favorable rate of return on the sale proceeds received, as compared to the

rental revenue currently earned pursuant to these leases. Please see Note 4

to the consolidated financial statements – Lease Accounting, for additional

information related to a lease renewal between us and Wellington Regional

      Medical Center, a wholly-owned subsidiary of UHS.


   •  In certain of our markets, the general real estate market has been

unfavorably impacted by increased competition/capacity and decreases in

occupancy and rental rates which may adversely impact our operating results

and the underlying value of our properties.

• A number of legislative initiatives have recently been passed into law that

may result in major changes in the health care delivery system on a national

or state level to the operators of our facilities, including UHS. No

assurances can be given that the implementation of these new laws will not

have a material adverse effect on the business, financial condition or

results of operations of our operators.

• The potential indirect impact of the Tax Cuts and Jobs Act of 2017, signed

into law on December 22, 2017, which makes significant changes to corporate

and individual tax rates and calculation of taxes, which could potentially

impact our tenants and jurisdictions, both positively and negatively, in

which we do business, as well as the overall investment thesis for REITs.

• A subsidiary of UHS is our Advisor and our officers are all employees of a

wholly-owned subsidiary of UHS, which may create the potential for conflicts

of interest.

• Lost revenues resulting from the exercise of purchase options, lease

expirations and renewals and other transactions (see Note 4 to the condensed

consolidated financial statements – Lease Accounting for additional

disclosure related to lease expirations and subsequent vacancies that

occurred during the second and third quarters of 2019 and the fourth quarter

of 2021 on three specialty hospital facilities.

• Potential unfavorable tax consequences and reduced income resulting from an

inability to complete, within the statutory timeframes, anticipated tax

deferred like-kind exchange transactions pursuant to Section 1031 of the

Internal Revenue Code, if, and as, applicable from time-to-time.

• Our ability to continue to obtain capital on acceptable terms, including

      borrowed funds, to fund future growth of our business.


   •  The outcome and effects of known and unknown litigation, government

investigations, and liabilities and other claims asserted against us, UHS or

the other operators of our facilities. UHS and its subsidiaries are subject

to legal actions, purported shareholder class actions and shareholder

derivative cases, governmental investigations and regulatory actions and the

effects of adverse publicity relating to such matters. Since UHS comprised

approximately 37% of our consolidated revenues during the year ended

December 31, 2021, and since a subsidiary of UHS is our Advisor, you are

encouraged to obtain and review the disclosures contained in the Legal

Proceedings section of Universal Health Services, Inc.’s Forms 10-Q and

10-K, as publicly filed with the Securities and Exchange Commission. Those

      filings are the sole responsibility of UHS and are not incorporated by
      reference herein.

• Failure of UHS or the other operators of our hospital facilities to comply

with governmental regulations related to the Medicare and Medicaid licensing

and certification requirements could have a material adverse impact on our

      future revenues and the underlying value of the property.




                                       35
--------------------------------------------------------------------------------

• The potential unfavorable impact on our business of the deterioration in

national, regional and local economic and business conditions, including a

worsening of credit and/or capital market conditions, which may adversely

      affect our ability to obtain capital which may be required to fund the
      future growth of our business and refinance existing debt with near term
      maturities.

• A continuation in the deterioration in general economic conditions which has

resulted in increases in the number of people unemployed and/or insured and

likely increase the number of individuals without health insurance. Under

these circumstances, the operators of our facilities may experience declines

      in patient volumes which could result in decreased occupancy rates at our
      medical office buildings.

• A continuation of the worsening of the economic and employment conditions in

the United States would likely materially affect the business of our

operators, including UHS, which would likely unfavorably impact our future

bonus rental revenue (on one UHS hospital facility) and may potentially have

a negative impact on the future lease renewal terms and the underlying value

of the hospital properties.

• Real estate market factors, including without limitation, the supply and

demand of office space and market rental rates, changes in interest rates as

      well as an increase in the development of medical office condominiums in
      certain markets.

• The impact of property values and results of operations of severe weather

conditions, including the effects of hurricanes.

• Government regulations, including changes in the reimbursement levels under

the Medicare and Medicaid programs.

• The issues facing the health care industry that affect the operators of our

facilities, including UHS, such as: changes in, or the ability to comply

with, existing laws and government regulations; unfavorable changes in the

levels and terms of reimbursement by third party payors or government

programs, including Medicare (including, but not limited to, the potential

unfavorable impact of future reductions to Medicare reimbursements resulting

from the Budget Control Act of 2011, as discussed in the next bullet point

below) and Medicaid (most states have reported significant budget deficits

that have, in the past, resulted in the reduction of Medicaid funding to the

operators of our facilities, including UHS); demographic changes; the

ability to enter into managed care provider agreements on acceptable terms;

an increase in uninsured and self-pay patients which unfavorably impacts the

collectability of patient accounts; decreasing in-patient admission trends;

technological and pharmaceutical improvements that may increase the cost of

      providing, or reduce the demand for, health care, and; the ability to
      attract and retain qualified medical personnel, including physicians.


   •  The Budget Control Act of 2011 imposed annual spending limits for most
      federal agencies and programs aimed at reducing budget deficits by $917
      billion between 2012 and 2021, according to a report released by the

Congressional Budget Office. Among its other provisions, the law established

a bipartisan Congressional committee, known as the Joint Select Committee on

Deficit Reduction (the “Joint Committee“), which was tasked with making

recommendations aimed at reducing future federal budget deficits by an

additional $1.5 trillion over 10 years. The Joint Committee was unable to

reach an agreement by the November 23, 2011 deadline and, as a result,

across-the-board cuts to discretionary, national defense and Medicare

spending were implemented on March 1, 2013 resulting in Medicare payment

reductions of up to 2% per fiscal year with a uniform percentage reduction

across all Medicare programs. The Bipartisan Budget Act of 2015, enacted on

November 2, 2015, continued the 2% reductions to Medicare reimbursement

imposed under the Budget Control Act of 2011. Recent legislation has

suspended payment reductions through December 31, 2021 in exchange for

extended cuts through 2030. Subsequent legislation extended the payment

reduction suspension through March 31, 2022, with a 1% payment reduction

from then until June 30, 2022 and the full 2% payment reduction

thereafter. We cannot predict whether Congress will restructure the

implemented Medicare payment reductions or what other federal budget deficit

reduction initiatives may be proposed by Congress going forward. We also

cannot predict the effect these enactments will have on the operators of our

properties (including UHS), and thus, our business.

• An increasing number of legislative initiatives have been passed into law

that may result in major changes in the health care delivery system on a

national or state level. Legislation has already been enacted that has

eliminated the penalty for failing to maintain health coverage that was part

of the original Patient Protection and Affordable Care Act (the “ACA”).

President Biden is expected to undertake executive actions that will

strengthen the ACA and may reverse the policies of the prior administration.

To date, the Biden administration has issued executive orders implementing a

special enrollment period permitting individuals to enroll in health plans

outside of the annual open enrollment period and reexamining policies that

may undermine the ACA or the Medicaid program. The ARPA’s expansion of

subsidies to purchase coverage through an exchange is anticipated to

increase exchange enrollment. The Trump Administration had directed the

issuance of final rules: (i) enabling the formation of association health

plans that would be exempt from certain ACA requirements such as the

provision of essential health benefits; (ii) expanding the availability of

short-term, limited duration health insurance, (iii) eliminating

cost-sharing reduction payments to insurers that would otherwise offset

deductibles and other out-of-pocket expenses for health plan enrollees at or

below 250 percent of the federal poverty level; (iv) relaxing requirements

for state innovation waivers that could reduce enrollment in the individual

and small group markets and lead to additional enrollment in short-term,

      limited duration insurance and association health plans; and (v)
      incentivizing the use of health reimbursement




                                       36
--------------------------------------------------------------------------------

arrangements by employers to permit employees to purchase health insurance

in the individual market. The uncertainty resulting from these Executive

Branch policies had led to reduced Exchange enrollment in 2018, 2019 and

2020, and is expected to further worsen the individual and small group

market risk pools in future years. It is also anticipated that these

policies, to the extent that they remain as implemented, may create

additional cost and reimbursement pressures on hospitals, including ours. In

addition, while attempts to repeal the entirety of the ACA have not been

successful to date, a key provision of the ACA was eliminated as part of the

Tax Cuts and Jobs Act and on December 14, 2018, a federal U.S. District

Court Judge in Texas ruled the entire ACA is unconstitutional. That ruling

was appealed and on December 18, 2019, the Fifth Circuit Court of Appeals

voted 2-1 to strike down the ACA individual mandate as unconstitutional. The

case was ultimately appealed to the United States Supreme Court, which

decided in California v. Texas that the plaintiffs in the matter lacked

      standing to bring their constitutionality claims. As a result, the
      Legislation will continue to remain law, in its entirety, likely for the
      foreseeable future.

• There can be no assurance that if any of the announced or proposed changes

described above are implemented there will not be negative financial impact

on the operators of our hospitals, which material effects may include a

potential decrease in the market for health care services or a decrease in

the ability of the operators of our hospitals to receive reimbursement for

health care services provided which could result in a material adverse

effect on the financial condition or results of operations of the operators

of our properties, and, thus, our business.

• Competition for properties include, but are not limited to, other REITs,

private investors and firms, banks and other companies, including UHS. In

addition, we may face competition from other REITs for our tenants.



   •  The operators of our facilities face competition from other health care
      providers, including physician owned facilities and other competing
      facilities, including certain facilities operated by UHS but the real
      property of which is not owned by us. Such competition is experienced in
      markets including, but not limited to, McAllen, Texas, the site of our
      McAllen Medical Center, a 370-bed acute care hospital.

• Changes in, or inadvertent violations of, tax laws and regulations and other

factors that can affect REITs and our status as a REIT, including possible

future changes to federal tax laws that could materially impact our ability

      to defer gains on divestitures through like-kind property exchanges.


• The individual and collective impact of the changes made by the CARES Act on

REITs and their security holders are uncertain and may not become evident

for some period of time; it is also possible additional legislation could be

enacted in the future as a result of the COVID-19 pandemic which may affect

      the holders of our securities.


   •  Should we be unable to comply with the strict income distribution

requirements applicable to REITs, utilizing only cash generated by operating

activities, we would be required to generate cash from other sources which

could adversely affect our financial condition.

• Our ownership interest in four LLCs/LPs in which we hold non-controlling

equity interests. In addition, pursuant to the operating and/or partnership

agreements of the four LLCs/LPs in which we continue to hold non-controlling

ownership interests, the third-party member and the Trust, at any time,

potentially subject to certain conditions, have the right to make an offer

(“Offering Member”) to the other member(s) (“Non-Offering Member”) in which

it either agrees to: (i) sell the entire ownership interest of the Offering

Member to the Non-Offering Member (“Offer to Sell”) at a price as determined

by the Offering Member (“Transfer Price”), or; (ii) purchase the entire

ownership interest of the Non-Offering Member (“Offer to Purchase”) at the

equivalent proportionate Transfer Price. The Non-Offering Member has 60 to

90 days to either: (i) purchase the entire ownership interest of the

Offering Member at the Transfer Price, or; (ii) sell its entire ownership

interest to the Offering Member at the equivalent proportionate Transfer

Price. The closing of the transfer must occur within 60 to 90 days of the

acceptance by the Non-Offering Member. Please see Note 5 to the condensed

consolidated financial statements – Summarized Financial Information of

Equity Affiliates for additional disclosure related to a fourth quarter,

2021 transaction between us and the minority partner in Grayson Properties,

      LP.


  • Fluctuations in the value of our common stock.

• Other factors referenced herein or in our other filings with the Securities

and Exchange Commission.



Given these uncertainties, risks and assumptions, you are cautioned not to place
undue reliance on such forward-looking statements. Our actual results and
financial condition, including the operating results of our lessees and the
facilities leased to subsidiaries of UHS, could differ materially from those
expressed in, or implied by, the forward-looking statements.

Forward-looking statements speak only as of the date the statements are made. We
assume no obligation to publicly update any forward-looking statements to
reflect actual results, changes in assumptions or changes in other factors
affecting forward-looking




                                       37
--------------------------------------------------------------------------------


information, except as may be required by law. All forward-looking statements
attributable to us or persons acting on our behalf are expressly qualified in
their entirety by this cautionary statement.

Critical Accounting Policies and Estimates


The preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires us to make estimates
and assumptions that affect the amounts reported in our consolidated financial
statements and accompanying notes.

We consider our critical accounting policies to be those that require us to make
significant judgments and estimates when we prepare our financial statements,
including the following:

Purchase Accounting for Acquisition of Investments in Real Estate: Purchase
accounting is applied to the assets and liabilities related to most real estate
investments acquired from third parties. In accordance with current accounting
guidance, we account for most of our property acquisitions as acquisitions of
assets, which requires the capitalization of acquisition costs to the underlying
assets and prohibits the recognition of goodwill or bargain purchase gains. The
fair value of most of the real estate acquired is allocated to the acquired
tangible assets, consisting primarily of land, building and tenant improvements,
and identified intangible assets and liabilities, consisting of the value of
above-market and below-market leases, and acquired ground leases, based in each
case on their fair values. Loan premiums, in the case of above market rate
assumed loans, or loan discounts, in the case of below market assumed loans, are
recorded based on the fair value of any loans assumed in connection with
acquiring the real estate. Please see additional disclosure below regarding
"Financing Assets".

The fair values of the tangible assets of an acquired property are determined
based on comparable land sales for land and replacement costs adjusted for
physical and market obsolescence for the improvements. The fair values of the
tangible assets of an acquired property are also determined by valuing the
property as if it were vacant, and the "as-if-vacant" value is then allocated to
land, building and tenant improvements based on management's determination of
the relative fair values of these assets. Management determines the as-if-vacant
fair value of a property based on assumptions that a market participant would
use, which is similar to methods used by independent appraisers. In addition,
there is intangible value related to having tenants leasing space in the
purchased property, which is referred to as in-place lease value. Such value
results primarily from the buyer of a leased property avoiding the costs
associated with leasing the property and also avoiding rent losses and
unreimbursed operating expenses during the hypothetical lease-up period. Factors
considered by management in performing these analyses include an estimate of
carrying costs during the expected lease-up periods considering current market
conditions and costs to execute similar leases. In estimating carrying costs,
management includes real estate taxes, insurance and other operating expenses
and estimates of lost rental revenue during the expected lease-up periods based
on current market demand. Management also estimates costs to execute similar
leases including leasing commissions, tenant improvements, legal and other
related costs. The value of in-place leases are amortized to expense over the
remaining initial terms of the respective leases.

In allocating the fair value of the identified intangible assets and liabilities
of an acquired property, above-market and below-market in-place lease values are
recorded based on the present value (using an interest rate which reflects the
risks associated with the leases acquired) of the difference between (i) the
contractual amounts to be paid pursuant to the in-place leases and
(ii) estimated fair market lease rates from the perspective of a market
participant for the corresponding in-place leases, measured, for above-market
leases, over a period equal to the remaining non-cancelable term of the lease
and, for below-market leases, over a period equal to the initial term plus any
below market fixed rate renewal periods. The capitalized above-market lease
values are amortized as a reduction of rental income over the remaining
non-cancelable terms of the respective leases. The capitalized below-market
lease values, also referred to as acquired lease obligations, are amortized as
an increase to rental income over the initial terms of the respective leases.



                                       38
--------------------------------------------------------------------------------


Financing Assets:  As discussed in Note 2 - Relationship with UHS and Related
Party Transactions, on December 31, 2021 we entered into an asset purchase and
sale agreement with UHS and certain of its affiliates. Pursuant to the
agreement, UHS purchased from us the real estate assets of the Inland Valley
Campus of Southwest Healthcare System ("Inland Valley") and transferred to us
the real estate assets of Aiken Regional Medical Center ("Aiken") and Canyon
Creek Behavioral Health ("Canyon Creek"). In connection with this transaction,
Aiken and Canyon Creek (as lessees), entered into a master lease and individual
property leases (with us as lessor) for initial lease terms of approximately
twelve years, ending on December 31, 2033. As a result of UHS' purchase option
within the lease agreements of Aiken and Canyon Creek, the transaction is
accounted for as a failed sale leaseback in accordance with U.S. GAAP and we
have accounted for the transaction with UHS as a financing arrangement. A
portion of the monthly lease payment to us from UHS will be recorded to interest
income based upon an imputed interest rate and the remainder will reduce the
outstanding financing receivable. In connection with this transaction, our
Consolidated Balance Sheet at December 31, 2021 reflects a financing receivable
of $82.4 million, which is the aggregate fair value of the real estate assets
that we received as part of the transaction (Aiken and Canyon Creek). As of
December 31, 2021 there are no indicators of impairment and the financing
receivable will be assessed for recoverability in accordance with our asset
impairment policy.

Asset Impairment:  We review each of our properties for indicators that its
carrying amount may not be recoverable. Examples of such indicators may include
a significant decrease in the market price of the property, a change in the
expected holding period for the property, a significant adverse change in how
the property is being used or expected to be used based on the underwriting at
the time of acquisition, an accumulation of costs significantly in excess of the
amount originally expected for the acquisition or development of the property,
or a history of operating or cash flow losses of the property. When such
impairment indicators exist, we review an estimate of the future undiscounted
net cash flows (excluding interest charges) expected to result from the real
estate investment's use and eventual disposition and compare that estimate to
the carrying value of the property. We consider factors such as future operating
income, trends and prospects, as well as the effects of leasing demand,
competition and other factors. If our future undiscounted net cash flow
evaluation indicates that we are unable to recover the carrying value of a real
estate investment, an impairment loss is recorded to the extent that the
carrying value exceeds the estimated fair value of the property. The evaluation
of anticipated cash flows is highly subjective and is based in part on
assumptions regarding future occupancy, rental rates and capital requirements
that could differ materially from actual results in future periods. Since cash
flows on properties considered to be long-lived assets to be held and used are
considered on an undiscounted basis to determine whether the carrying value of a
property is recoverable, our strategy of holding properties over the long-term
directly decreases the likelihood of their carrying values not being recoverable
and therefore requiring the recording of an impairment loss. If our strategy
changes or market conditions otherwise dictate an earlier sale date, an
impairment loss may be recognized and such loss could be material. If we
determine that the asset fails the recoverability test, the affected assets must
be reduced to their fair value.

We generally estimate the fair value of rental properties utilizing a discounted
cash flow analysis that includes projections of future revenues, expenses and
capital improvement costs that a market participant would use based on the
highest and best use of the asset, which is similar to the income approach that
is commonly utilized by appraisers. In certain cases, we may supplement this
analysis by obtaining outside broker opinions of value or third party
appraisals.

In considering whether to classify a property as held for sale, we consider
factors such as whether management has committed to a plan to sell the property,
the property is available for immediate sale in its present condition for a
price that is reasonable in relation to its current value, the sale of the
property is probable, and actions required for management to complete the plan
indicate that it is unlikely that any significant changes will made to the
plan. If all the criteria are met, we classify the property as held for sale.
Upon being classified as held for sale, depreciation and amortization related to
the property ceases and it is recorded at the lower of its carrying amount or
fair value less cost to sell. The assets and related liabilities of the property
are classified separately on the consolidated balance sheets for the most recent
reporting period. Only those assets held for sale that constitute a strategic
shift or that will have a major effect on our operations are classified as
discontinued operations.

An other than temporary impairment of an investment in an unconsolidated LLC is
recognized when the carrying value of the investment is not considered
recoverable based on evaluation of the severity and duration of the decline in
value, including projected declines in cash flow. To the extent impairment has
occurred, the excess carrying value of the asset over its estimated fair value
is charged to income.

Federal Income Taxes:  No provision has been made for federal income tax
purposes since we qualify as a REIT under Sections 856 to 860 of the Internal
Revenue Code of 1986, and intend to continue to remain so qualified.  To qualify
as a REIT, we must meet certain organizational and operational requirements,
including a requirement to distribute at least 90% of our annual REIT taxable
income to shareholders. As a REIT, we generally will not be subject to federal,
state or local income tax on income that we distribute as dividends to our
shareholders.



                                       39
--------------------------------------------------------------------------------


We are subject to a federal excise tax computed on a calendar year basis. The
excise tax equals 4% of the amount by which 85% of our ordinary income plus 95%
of any capital gain income for the calendar year exceeds cash distributions
during the calendar year, as defined. No provision for excise tax has been
reflected in the financial statements as no tax was due.

Earnings and profits, which determine the taxability of dividends to
shareholders, will differ from net income reported for financial reporting
purposes due to the differences for federal tax purposes in the cost basis of
assets and in the estimated useful lives used to compute depreciation and the
recording of provision for investment losses.

Results of Operations

Year ended December 31, 2021 as compared to the year ended December 31, 2020:

For the year ended December 31, 2021, net income was $109.2 million as compared
to $19.4 million during 2020. The $89.7 million increase was primarily
attributable to:

$87.3 million increase resulting from gains recorded on various divestitures

of real estate assets including the divestiture of two MOBs, as well as the

divestiture of the Inland Valley Campus of Southwest Healthcare System as

part of an asset purchase and sale transaction with UHS (for additional

disclosure, please see Note 3 to the consolidated financial statements,

      Asset Purchase and Sale Transaction, Acquisitions, Divestitures and New
      Construction);

$2.2 million of other combined net increases, including increased net income

experienced at various properties including the income recorded in

connection with the newly constructed Clive Behavioral Health facility that

was substantially completed in December, 2020;

$790,000 increase in bonus rentals earned on the three hospital facilities

      leased to wholly-owned subsidiaries of UHS during 2020 and 2021, and;


  • $546,000 decrease resulting from an increase in interest expense.






                                       40
--------------------------------------------------------------------------------



Total revenues increased by $6.2 million, or 7.9%, during 2021 as compared to
2020. The increase consisted primarily of the rentals earned on the Clive
Behavioral Health facility, increased bonus rentals earned on certain hospitals
leased to wholly-owned subsidiaries of UHS and increases in rentals earned at
various other properties including properties acquired during 2021 and late in
2020.

Our other operating expenses include expenses related to the consolidated
medical office buildings and two specialty facilities that were vacant during
2021 (as discussed herein), which totaled $20.8 million and $19.8 million for
the years ended December 31, 2021 and 2020, respectively. A large portion of the
expenses associated with our medical office buildings is passed on directly to
the tenants either directly as tenant reimbursements of common area maintenance
expenses or included in base rental amounts. Tenant reimbursements for operating
expenses are accrued as revenue in the same period during which the related
expenses are incurred. Our operating expenses for 2021 and 2020 include
approximately $737,000 and $677,000 for the years ended December 31, 2021 and
2020, respectively, of aggregate operating expenses related to two vacant
specialty facilities located in Corpus Christi, Texas and Evansville, Indiana.

Funds from operations ("FFO") is a widely recognized measure of performance for
Real Estate Investment Trusts ("REITs"). We believe that FFO and FFO per diluted
share, which are non-GAAP financial measures, are helpful to our investors as
measures of our operating performance. We compute FFO in accordance with
standards established by the National Association of Real Estate Investment
Trusts ("NAREIT"), which may not be comparable to FFO reported by other REITs
that do not compute FFO in accordance with the NAREIT definition, or that
interpret the NAREIT definition differently than we interpret the definition.
FFO adjusts for the effects of certain items, such as gains on transactions that
occurred during the periods presented. To the extent a REIT recognizes a gain or
loss with respect to the sale of incidental assets, the REIT has the option to
exclude or include such gains and losses in the calculation of FFO. We have
opted to exclude gains and losses from sales of incidental assets in our
calculation of FFO. FFO does not represent cash generated from operating
activities in accordance with GAAP and should not be considered to be an
alternative to net income determined in accordance with GAAP. In addition, FFO
should not be used as: (i) an indication of our financial performance determined
in accordance with GAAP; (ii) an alternative to cash flow from operating
activities determined in accordance with GAAP; (iii) a measure of our liquidity,
or; (iv) an indicator of funds available for our cash needs, including our
ability to make cash distributions to shareholders.

Below is a reconciliation of our reported net income to FFO for 2021 and 2020
(in thousands):
                                                            2021             2020
Net income                                              $    109,166     $     19,447

Depreciation and amortization expense on consolidated
investments

                                                   27,478        

25,581

Depreciation and amortization expense on
unconsolidated affiliates                                      1,549        

1,202

Gains on divestitures of real estate assets                  (87,314 )      

Funds From Operations                                   $     50,879     $  

46,230


Weighted average number of shares outstanding -
Diluted                                                       13,779        

13,765

Funds From Operations per diluted share                 $       3.69     $  

3.36



Our FFO increased by $4.6 million, or $.33 per diluted share, during 2021 as
compared to 2020 due to: (i) the net increase of $2.4 million, or $.17 per
diluted share, resulting from the increase in net income of $89.7 million, or
$6.51 per diluted share, as discussed above, excluding the gain on divestitures
of $87.3 million, or $6.34 per diluted share, recorded during 2021, and; (ii) a
favorable impact of $2.2 million, or $.16 per diluted share, resulting from an
increase in depreciation and amortization expense on consolidated and
unconsolidated affiliates, largely due to the depreciation expense recorded in
connection with the Clive Behavioral Health facility which was completed in
December, 2020.

During 2021, we had a total of 56 new or renewed leases related to the medical
office buildings as indicated in Item 2. Properties, in which we have
significant investments, some of which are accounted for by the equity method.
These leases comprised approximately 29% of the aggregate rentable square feet
of these properties (26% related to renewed leases and 3% related to new
leases). During 2020, we had a total of 39 new or renewed leases related to the
medical office buildings, in which we have significant investments, some of
which are accounted for by the equity method. These leases comprised
approximately 30% of the aggregate rentable square feet of these properties (21%
related to renewed leases and 9% related to new leases).

Rental rates, tenant improvement costs and rental concessions vary from property
to property based upon factors such as, but not limited to, the current
occupancy and age of our buildings, local overall economic conditions, proximity
to hospital campuses and the vacancy rates, rental rates and capacity of our
competitors in the market. In connection with lease renewals executed during
each year, the weighted-average rental rates, as compared to rental rates on the
expired leases, increased by approximately 1% during 2021 and decreased by
approximately 1% during 2020. The weighted-average tenant improvement costs
associated with new or renewed leases was approximately $5 and $18 per square
foot during 2021 and 2020, respectively. The weighted-average leasing
commissions on the new and renewed leases commencing during each year was
approximately 2% of base rental revenue over the term of the leases during 2021
and 3% of base rental revenue over the term of the leases during 2020. The
average aggregate value of the tenant concessions, generally consisting of rent
abatements, provided in connection with new and renewed leases commencing during
each



                                       41
--------------------------------------------------------------------------------


year was approximately 0.8% and 0.9% of the future aggregate base rental revenue
over the lease terms during 2021 and 2020, respectively. Rent abatements were,
or will be, recognized in our results of operations under the straight-line
method over the lease term regardless of when payments are due.

Other Operating Results

Interest Expense:

Reflected below are the components of our interest expense during the years
ended December 31, 2021 and December 31, 2020 (amounts in thousands):


                                          2021        2020
Revolving credit agreement               $ 4,282     $ 4,608
Mortgage interest                          2,505       2,600

Interest rate swaps expense, net (a.) 1,283 737
Amortization of financing fees

               790         765
Amortization of fair value of debt           (51 )       (52 )

Capitalized interest on major projects – (395 )
Interest expense, net

                    $ 8,809     $ 8,263


(a.) Represents net interest paid by us to the counterparties pursuant to

           three interest rates SWAPs with a combined notional amount of $140
           million.


Interest expense increased by $546,000 during 2021 as compared to 2020 due
to: (i) a $326,000 decrease in interest expense on our revolving credit
agreement resulting from a decrease in our average cost of borrowings (1.69%
effective rate during 2021 as compared to 2.10% effective rate during 2020),
partially offset by an increase in our average outstanding borrowings ($253.5
million during 2021 as compared to $219.1 million during 2020); (ii) a $546,000
net increase in interest expense related to interest rate swaps; (iii) a $95,000
decrease in mortgage interest expense; (iv) a $395,000 increase in interest
expense due to a decrease in capitalized interest on major projects (no
capitalized interest recorded during 2021 since both newly constructed
facilities were substantially completed in December, 2020), and; (v) a $26,000
increase due to an increase in amortization of financing fees and fair value of
debt.


Disclosures Related to Certain Hospital Facilities


Please refer to Note 4 to the consolidated financial statements - Lease
Accounting, for additional information regarding certain of our hospital
facilities including the lease renewal for Wellington Regional Medical Center
located in West Palm Beach, Florida, information related to vacant facilities
located in Evansville, Indiana; Corpus Christi, Texas, and Chicago, Illinois,
and disclosure regarding the asset purchase and sale agreement with wholly-owned
subsidiaries of UHS that was completed on December 31, 2021.


Effects of Inflation


The healthcare industry is very labor intensive and salaries and benefits
related to the employees of our tenants are subject to inflationary pressures,
as are supply costs, construction costs and medical equipment and other costs.
The nationwide shortage of nurses and other clinical staff and support personnel
has been a significant operating issue facing healthcare providers. In
particular, the healthcare industry continues to experience a shortage of nurses
and other clinical staff and support personnel in certain geographic areas,
which has been exacerbated by the COVID­19 pandemic. The operators of our
hospital properties are treating patients with COVID­19 and, in some areas, the
increased demand for care is putting a strain on their resources and staff,
which has required them to utilize higher­cost temporary labor and pay premiums
above standard compensation for essential workers. The length and extent of the
disruptions caused by the COVID­19 pandemic are currently unknown; however, the
tenants of our facilities expect such disruptions to continue into 2022 and
potentially throughout the duration of the pandemic and beyond. This staffing
shortage may require our tenants to further enhance wages and benefits to
recruit and retain nurses and other clinical staff and support personnel or
require them to hire expensive temporary personnel. Their ability to pass on
increased costs associated with providing healthcare to Medicare and Medicaid
patients is limited due to various federal, state and local laws which have been
enacted that, in certain cases, limit their ability to increase prices.
Therefore, there can be no assurance that these factors will not have a material
adverse effect on the future results of operations of the operators of our
facilities which may affect their ability to make lease payments to us. In
addition, we have experienced cost increases related to the construction of new
facilities and renovations at existing facilities which could have an adverse
effect on our future results of operations.

Most of our leases contain provisions designed to mitigate the adverse impact of
inflation. Our hospital leases require all building operating expenses,
including maintenance, real estate taxes and other costs, to be paid by the
lessee. In addition, most of our MOB leases require the tenant to pay an
allocable share of operating expenses, including common area maintenance costs,
insurance



                                       42
--------------------------------------------------------------------------------


and real estate taxes. These provisions may reduce our exposure to increases in
operating costs resulting from inflation. To the extent that some leases do not
contain such provisions, our future operating results may be adversely impacted
by the effects of inflation.

Liquidity and Capital Resources

Year ended December 31, 2021 as compared to December 31, 2020:

Net cash provided by operating activities

Net cash provided by operating activities was $47.7 million during 2021 as
compared to $44.2 million during 2020. The $3.5 million net increase was
attributable to:

• A favorable change of $4.4 million due to an increase in net income

plus/minus the adjustments to reconcile net income to net cash provided by

operating activities (depreciation and amortization, amortization related

to above/below market leases, amortization of debt premium, amortization of

       deferred financing costs, stock-based compensation expense and gains on
       divestitures of real estate assets), as discussed above;

• an unfavorable change of $763,000 in tenant reserves, deposits and deferred

       and prepaid rents;


  • an unfavorable change of $743,000 in lease receivables, and;




                                       43
--------------------------------------------------------------------------------



  • other combined net favorable changes of $652,000.

Net cash used in investing activities

Net cash used in investing activities was $24.4 million during 2021 as compared
to $27.2 million during 2020.

2021:

During 2021, $24.4 million of net cash was used in investing activities as
follows:

• spent $14.1 million for additions to real estate investments, including

       $3.3 million of construction costs related to the newly constructed,
       100-bed behavioral health care hospital located in Clive, Iowa, that was
       substantially completed in late December, 2020; $2.9 million of

constructions costs related to the construction of a new MOB, and tenant

improvements at various MOBs;

• spent approximately $16.8 million in equity investments in unconsolidated

LLCs, including $13.2 million to repay a mortgage loan upon its scheduled

maturity in September, 2021;

• spent approximately $13.0 million on the acquisition of the Fire Mesa

       office building in late May, 2021, as discussed in Note 3 to the
       consolidated financial statements;


  • spent $3.5 million to advance a member loan to an unconsolidated LP;

• spent approximately $3.1 million to acquire the minority interest in a

majority-owned LP, as discussed in Note 2 to the consolidated financial

statements;

• spent approximately $2.8 million as part of the asset purchase and sale

transaction with UHS, as discussed in Note 2 to the consolidated financial

       statements;


  • spent $200,000 in a deposit on real estate assets;

• received approximately $28.1 million of aggregate net cash proceeds, ($15.2

million of which is held by the qualified third-party intermediary utilized

for the series of anticipated tax-deferred like-kind exchange transactions

pursuant to Section 1031 of the Internal Revenue Code, as amended) for the

divestitures of the Children’s Clinic of Springdale and the Auburn Medical

Office Building II, as discussed in Note 3 to the consolidated financial

       statements;


  • received $418,000 of cash in excess of income from LLCs, and;

• our cash balance reflects an increase of $528,000 as a result of recording

on a consolidated basis, an LP in which we acquired the third-party

minority ownership interest, as discussed in Note 2 to the consolidated

financial statements.

2020:

During 2020, $27.2 million of net cash was used in investing activities as
follows:

• spent $28.3 million for additions to real estate investments, including

$22.2 million of construction costs related to the 100-bed behavioral

health care hospital located in Clive, Iowa, that was substantially

completed in December, 2020, and tenant improvements at various MOBs;


  • spent $3.2 million in equity investments in unconsolidated LLCs;

• spent $2.3 million on the acquisition of the Sand Point Medical Properties

building in late December, 2020, as discussed in Note 3 to the consolidated

financial statements, and;

• received $6.5 million of cash in excess of income from LLCs, including $5.2

       million of cash proceeds generated from a construction loan obtained by
       Grayson Properties II during the second quarter of 2020.


Net cash used in financing activities

Net cash used in financing activities was $6.5 million during 2021, as compared
to $17.4 million during 2020.

2021:

The $6.5 million of cash used in financing activities during 2021 consisted of:

• paid approximately $38.5 million of dividends;

• received $35.7 million of additional net borrowings on our revolving line

       of credit;


    •  paid approximately $2.1 million on mortgage notes payable that are
       non-recourse to us;




                                       44
--------------------------------------------------------------------------------

• paid approximately $1.8 million of financing costs, related primarily to

the July, 2021 amended and restated revolving credit agreement, and;

• received $215,000 from this issuance of shares of beneficial interest

       pursuant to our dividend reinvestment plan.


2020:

The $17.4 million of cash used in financing activities during 2020 consisted of:

• paid $38.0 million of dividends;

• received $23.3 million of additional net borrowings on our revolving line

of credit;

• paid $1.9 million on mortgage notes payable that are non-recourse to us;

• paid $467,000 of financing costs related to the revolving credit agreement,

including amendment fees, and;

• paid $235,000 to repurchase shares of our common stock in connection with

income tax withholding obligations related to stock-based compensation.

Additional cash flow and dividends paid information for 2021 and 2020:


As indicated on our consolidated statements of cash flows, we generated net cash
provided by operating activities of $47.7 million during 2021 and $44.2 million
during 2020. As also indicated on our statements of cash flows, non-cash
expenses including depreciation and amortization expense, amortization related
to above/below market leases, amortization of debt premium, amortization of
deferred financing costs and stock-based compensation expense, as well as gains
on divestitures of real estate assets (as applicable), are the primary
differences between our net income and net cash provided by operating activities
for each year.

We declared and paid dividends of $38.5 million during 2021 and $38.0 million
during 2020. During 2021, the $47.7 million of net cash provided by operating
activities was approximately $9.2 million greater than the $38.5 million of
dividends paid during 2021. During 2020, the $44.2 million of net cash provided
by operating activities was approximately $6.2 million greater than the $38.0
million of dividends paid during 2020.

As indicated in the cash flows from investing activities and cash flows from
financing activities sections of the statements of cash flows, there were
various other sources and uses of cash during each of the last three years. From
time to time, various other sources and uses of cash may include items such as
investments and advances made to/from LLCs, additions to real estate
investments, acquisitions/divestiture of properties, net borrowings/repayments
of debt, and proceeds generated from the issuance of equity. Therefore, in any
given period, the funding source for our dividend payments is not wholly
dependent on the operating cash flow generated by our properties. Rather, our
dividends as well as our capital reinvestments into our existing properties,
acquisitions of real property and other investments are funded based upon the
aggregate net cash inflows or outflows from all sources and uses of cash from
the properties we own either in whole or through LLCs, as outlined above.

In determining and monitoring our dividend level on a quarterly basis, our
management and Board of Trustees consider many factors in determining the amount
of dividends to be paid each period. These considerations primarily include:
(i) the minimum required amount of dividends to be paid in order to maintain our
REIT status; (ii) the current and projected operating results of our properties,
including those owned in LLCs, and; (iii) our future capital commitments and
debt repayments, including those of our LLCs. Based upon the information
discussed above, as well as consideration of projections and forecasts of our
future operating cash flows, management and the Board of Trustees have
determined that our operating cash flows have been sufficient to fund our
dividend payments. Future dividend levels will be determined based upon the
factors outlined above with consideration given to our projected future results
of operations.

We expect to finance all capital expenditures and acquisitions and pay dividends
utilizing internally generated and additional funds. Additional funds may be
obtained through: (i) borrowings under our $375 million revolving credit
agreement (which had $99.9 million of available borrowing capacity, net of
outstanding borrowings and letters of credit as of December 31, 2021);
(ii) borrowings under or refinancing of existing third-party debt pursuant to
mortgage loan agreements entered into by our consolidated and unconsolidated
LLCs/LPs; (iii) the issuance of equity pursuant to our at-the-market ("ATM")
equity issuance program, and/or; (iv) the issuance of other long-term debt.

We believe that our operating cash flows, cash and cash equivalents, available
borrowing capacity under our revolving credit agreement and access to the
capital markets provide us with sufficient capital resources to fund our
operating, investing and financing requirements for the next twelve months,
including providing sufficient capital to allow us to make distributions
necessary to enable us to continue to qualify as a REIT under Sections 856 to
860 of the Internal Revenue Code of 1986. In the event we need to access



                                       45
--------------------------------------------------------------------------------


the capital markets or other sources of financing, there can be no assurance
that we will be able to obtain financing on acceptable terms or within an
acceptable time. Our inability to obtain financing on terms acceptable to us
could have a material unfavorable impact on our results of operations, financial
condition and liquidity.

Credit facilities and mortgage debt


Management routinely monitors and analyzes the Trust's capital structure in an
effort to maintain the targeted balance among capital resources including the
level of borrowings pursuant to our revolving credit facility, the level of
borrowings pursuant to non-recourse mortgage debt secured by the real property
of our properties and our level of equity including consideration of additional
equity issuances pursuant to our ATM equity issuance program. This ongoing
analysis considers factors such as the current debt market and interest rate
environment, the current/projected occupancy and financial performance of our
properties, the current loan-to-value ratio of our properties, the Trust's
current stock price, the capital resources required for anticipated acquisitions
and the expected capital to be generated by anticipated divestitures. This
analysis, together with consideration of the Trust's current balance of
revolving credit agreement borrowings, non-recourse mortgage borrowings and
equity, assists management in deciding which capital resource to utilize when
events such as refinancing of specific debt components occur or additional funds
are required to finance the Trust's growth.

On July 2, 2021, we entered into an amended and restated revolving credit
agreement ("Credit Agreement") to amend and restate the previously existing $350
million credit agreement, as amended and dated June 5, 2020 ("Prior Credit
Agreement"). Among other things, under the Credit Agreement, our aggregate
revolving credit commitment was increased to $375 million from $350 million. The
Credit Agreement, which is scheduled to mature on July 2, 2025, provides for a
revolving credit facility in an aggregate principal amount of $375 million,
including a $40 million sublimit for letters of credit and a $30 million
sublimit for swingline/short-term loans. Under the terms of the Credit
Agreement, we may request that the revolving line of credit be increased by up
to an additional $50 million. Borrowings under the new facility are guaranteed
by certain subsidiaries of the Trust. In addition, borrowings under the new
facility are secured by first priority security interests in and liens on all
equity interests in most of the Trust's wholly-owned subsidiaries.

Borrowings under the Credit Agreement will bear interest annually at a rate
equal to, at our option, at either LIBOR (for one, three, or six months) or the
Base Rate, plus in either case, a specified margin depending on our ratio of
debt to total capital, as determined by the formula set forth in the Credit
Agreement. The applicable margin ranges from 1.10% to 1.35% for LIBOR loans and
0.10% to 0.35% for Base Rate loans. The initial applicable margin is 1.25% for
LIBOR loans and 0.25% for Base Rate loans. The Credit Agreement defines "Base
Rate" as the greatest of (a) the Administrative Agent's prime rate, (b) the
federal funds effective rate plus 1/2 of 1% and (c) one month LIBOR plus 1%. The
Trust will also pay a quarterly commitment fee ranging from 0.15% to 0.35%
(depending on the Trust's ratio of debt to asset value) of the average daily
unused portion of the revolving credit commitments. The Credit Agreement also
provides for options to extend the maturity date and borrowing availability for
two additional six-month periods.

The margins over LIBOR, Base Rate and the facility fee are based upon our total
leverage ratio. At December 31, 2021, the applicable margin over the LIBOR rate
was 1.25%, the margin over the Base Rate was 0.25% and the facility fee was
0.25%.

At December 31, 2021, we had $271.9 million of outstanding borrowings and $3.2
million of letters of credit outstanding under our Credit Agreement. We had
$99.9 million of available borrowing capacity, net of the outstanding borrowings
and letters of credit outstanding as of December 31, 2021. The carrying amount
and fair value of borrowings outstanding pursuant to the Credit Agreement was
$271.9 million at December 31, 2021. There are no compensating balance
requirements. The average amount outstanding under our Credit Agreement during
the years ended December 31, 2021 and 2020 was $253.5 million and $219.1
million, respectively, with corresponding effective interest rates of 2.2% and
2.4%, respectively, including commitment fees and interest rate swaps/caps. At
December 31, 2020, we had $236.2 million of outstanding borrowings outstanding
against our revolving credit agreement that was in effect at that time, $5.6
million of letters of credit outstanding against the agreement and $108.2
million of available borrowing capacity.

The Credit Agreement contains customary affirmative and negative covenants,
including limitations on certain indebtedness, liens, acquisitions and other
investments, fundamental changes, asset dispositions and dividends and other
distributions. The Credit Agreement also contains restrictive covenants
regarding the Trust's ratio of total debt to total assets, the fixed charge
coverage ratio, the ratio of total secured debt to total asset value, the ratio
of total unsecured debt to total unencumbered asset value, and minimum tangible
net worth, as well as customary events of default, the occurrence of which may
trigger an acceleration of amounts then outstanding under the Credit Agreement.
We are in compliance with all of the covenants in the Credit Agreement at
December 31, 2021 and were in compliance with all of the covenants in the Prior
Credit Agreement at December 31, 2020. We also believe that we would remain in
compliance if, based on the assumption that the majority of the potential new
borrowings will be used to fund investments, the full amount of our commitment
was borrowed.





                                       46
--------------------------------------------------------------------------------

The following table includes a summary of the required compliance ratios at
December 31, 2021 and December 31, 2020, giving effect to the covenants
contained in the Credit Agreements in effect on the respective dates (dollar
amounts in thousands):


                               December 31, 2021                   December 31, 2020
                         Covenant             UHT            Covenant             UHT
Tangible net worth      $   125,000       $   225,355       $   125,000       $   147,263
Total leverage                 < 60   %          43.1   %          < 60   %          44.8   %
Secured leverage               < 30   %           7.4   %          < 30   %           8.6   %
Unencumbered leverage          < 60   %          41.9   %          < 60   %          41.4   %
Fixed charge coverage       > 1.50x              4.8x           > 1.50x              4.7x


As indicated on the following table, we have various mortgages, all of which are
non-recourse to us and are not cross-collateralized, included on our
consolidated balance sheet as of December 31, 2021 and December 31, 2020
(amounts in thousands):
                                                            As of 12/31/2021                          As of 12/31/2020
                                                                               Outstanding              Outstanding
                                           Interest         Maturity             Balance                  Balance
Facility Name                                Rate             Date          (in thousands)(a.)         (in thousands)
700 Shadow Lane and Goldring MOBs fixed
rate
  mortgage loan (b.)                            4.54 %        June, 2022   $              5,210      $            5,437
BRB Medical Office Building fixed rate
mortgage loan (b.)                              4.27 %    December, 2022                  5,280                   5,505
Desert Valley Medical Center fixed rate
mortgage loan (b.)                              3.62 %     January, 2023                  4,356                   4,511
2704 North Tenaya Way fixed rate
mortgage loan                                   4.95 %    November, 2023                  6,418                   6,576
Summerlin Hospital Medical Office
Building III fixed
  rate mortgage loan                            4.03 %       April, 2024                 12,806                  13,043
Tuscan Professional Building fixed rate
mortgage loan                                   5.56 %        June, 2025                  2,343                   2,933
Phoenix Children's East Valley Care
Center fixed rate
  mortgage loan                                 3.95 %     January, 2030                  8,466                   8,718
Rosenberg Children's Medical Plaza
fixed rate mortgage loan                        4.42 %   September, 2033                 12,273                  12,508
Total, excluding net debt premium and
net financing fees                                                                       57,152                  59,231
  Less net financing fees                                                                  (376 )                  (477 )
  Plus net debt premium                                                                      90                     141
Total mortgage notes payable,
non-recourse to us, net                                                    $             56,866      $           58,895


(a.) All mortgage loans require monthly principal payments through maturity and

        either fully amortize or include a balloon principal payment upon
        maturity.


   (b.) This loan is scheduled to mature within the next twelve months, at which
        time we will decide whether to refinance pursuant to a new mortgage loan
        or by utilizing borrowings under our Credit Agreement.


The mortgages are secured by the real property of the buildings as well as
property leases and rents. The mortgages outstanding as of December 31, 2021 had
a combined carrying value of approximately $57.2 million and a combined fair
value of approximately $59.4 million. At December 31, 2020, we had various
mortgages, all of which were non-recourse to us, included in our consolidated
balance sheet. The combined outstanding balance of these various mortgages was
$59.2 million and these mortgages had a combined fair value of approximately
$62.0 million.

The fair value of our debt was computed based upon quotes received from
financial institutions. We consider these to be "level 2" in the fair value
hierarchy as outlined in the authoritative guidance for disclosure in connection
with debt instruments. Changes in market rates on our fixed rate debt impacts
the fair value of debt, but it has no impact on interest incurred or cash flow.

Contractual Obligations and Off Balance Sheet Arrangements


As of December 31, 2021 we are party to certain off balance sheet arrangements
consisting of standby letters of credit and equity and debt financing
commitments. Our outstanding letters of credit at December 31, 2021 totaled $3.2
million related to Grayson Properties II. As of December 31, 2020, our
outstanding letters of credit totaled $5.6 million related to Grayson Properties
II.



                                       47
--------------------------------------------------------------------------------


The following table summarizes the schedule of maturities of our outstanding
borrowing under our revolving credit facility ("Credit Agreement"), the
outstanding mortgages applicable to our properties recorded on a consolidated
basis and our other contractual obligations as of December 31, 2021 (amounts in
thousands):

                                                   Payments Due by Period (dollars in thousands)
                                                    Less than                                      More than
Debt and Contractual Obligation         Total         1 Year        1-3 years      3-5 years        5 years
Long-term non-recourse debt-fixed
(a) (b)                               $  57,152     $   12,197     $    25,442     $    1,540     $    17,973
Long-term debt-variable (c)             271,900              -               -        271,900               -
Estimated future interest payments
on debt outstanding as
  of December 31, 2021 (d)               23,249          5,991          10,115          3,445           3,698
Operating leases (e)                     35,580            618           1,235          1,235          32,492
Construction commitments (f)             36,152         36,152               -              -               -
Equity and debt financing
commitments                                   -              -               -              -               -

Total contractual obligations $ 424,033 $ 54,958 $ 36,792 $ 278,120 $ 54,163

(a) The mortgages are secured by the real property of the buildings as well as

property leases and rents. Property-specific debt is detailed above.

(b) Consists of non-recourse debt with an aggregate fair value of approximately

$59.4 million as of December 31, 2021. Changes in market rates on our fixed

rate debt impacts the fair value of debt, but it has no impact on interest

incurred or cash flow. Excludes $22.1 million of combined third-party debt

    outstanding as of December 31, 2021, that is non-recourse to us, at the
    unconsolidated LLCs in which we hold various non-controlling ownership
    interests (see Note 8 to the consolidated financial statements).

(c) Consists of $271.9 million of borrowings outstanding as of December 31, 2021

under the terms of our $375 million Credit Agreement which matures on July 2,

2025. The amount outstanding approximates fair value as of December 31, 2021.

(d) Assumes that all debt outstanding as of December 31, 2021, including

borrowings under the Credit Agreement, and the loans which are non-recourse

to us, remain outstanding until the stated maturity date of the debt

agreements at the same interest rates which were in effect as of December 31,

2021. We have the right to repay borrowings under the Credit Agreement at any

time during the term of the agreement, without penalty. Interest payments are

expected to be paid utilizing cash flows from operating activities or

borrowings under our revolving Credit Agreement.

(e) Reflects our future minimum operating lease payment obligations outstanding

as of December 31, 2021, as discussed in Note 4 to the consolidated financial

statements -Lease Accounting, in connection with ground leases at fourteen of

our consolidated properties.

(f) Consists of the remaining estimated construction costs related to an MOB

located in Denison, Texas, which was substantially completed in late 2020 as

well as construction costs for a new 85,000 rentable square foot MOB located

in Reno, Nevada which commenced construction in January, 2022. We are

required to build these facilities pursuant to agreements.

Acquisition and Divestiture Activity

Please see Note 3 to the consolidated financial statements for completed
transactions.
ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk

Market Risks Associated with Financial Instruments

LIBOR Transition


In 2017, the U.K. Financial Conduct Authority ("FCA") that regulates LIBOR
announced it intends to phase out LIBOR and stop compelling banks to submit
rates for its calculation.  In 2021, the FCA further announced that effective
January 1, 2022, the one week and two-month USD LIBOR tenors are no longer being
published, and all other USD LIBOR tenors will cease to be published after June
30, 2023.

The Federal Reserve Board and the Federal Reserve Bank of New York organized the
Alternative Reference Rates Committee which identified the Secured Overnight
Financing Rate ("SOFR") as its preferred alternative to USD-LIBOR in derivatives
and other financial contracts.  We are not able to predict how the markets will
respond to SOFR or any other alternative reference rate as the transition away
from LIBOR continues in the coming years.  Any changes adopted by FCA or other
governing bodies in the method used for determining LIBOR may result in a sudden
or prolonged increase or decrease in reported LIBOR.  If that were to occur, our
interest payments could change. In addition, uncertainty about the extent and
manner of future changes may result in interest rates and/or payments that are
higher or lower than if LIBOR were to remain available in its current form.



                                       48
--------------------------------------------------------------------------------


At December 31, 2021, we had contracts that are indexed to LIBOR, such as our
unsecured revolving credit facility and interest rate derivatives. We are
monitoring and evaluating the related risks, which include interest on loans or
amounts received and paid on derivative instruments. These risks arise in
connection with transitioning contracts to a new alternative rate, including any
resulting value transfer that may occur. The value of loans, securities, or
derivative instruments tied to LIBOR could also be impacted if LIBOR is limited
or discontinued. For some instruments, the method of transitioning to an
alternative rate may be challenging, as they may require negotiation with the
respective counterparty.  Our unsecured revolving credit facility contains
provisions specifying alternative interest rate calculations to be employed when
LIBOR ceases to be available as a benchmark.

We currently expect the LIBOR-indexed rates included in our debt agreements to
be available until June 30, 2023. We anticipate managing the transition to a
preferred alternative rate using the language set out in our agreements,
however, future market conditions may not allow immediate implementation of
desired modifications and we may incur significant associated costs in doing so.
We will continue to monitor and evaluate the potential impact on our debt
payments and value of our related debt, however, we are not able to predict
when LIBOR-indexed rates (other than one week and two-month tenors which are not
included in our debt agreements and are no longer being published) will cease to
be available.

Financial Instruments

In March 2020, we entered into an interest rate swap agreement on a total
notional amount of $55 million with a fixed interest rate of 0.565% that we
designated as a cash flow hedge. The interest rate swap became effective on
March 25, 2020 and is scheduled to mature on March 25, 2027. If the one-month
LIBOR is above 0.565%, the counterparty pays us, and if the one-month LIBOR is
less than 0.565%, we pay the counterparty, the difference between the fixed rate
of 0.565% and one-month LIBOR.

In January 2020, we entered into an interest rate swap agreement on a total
notional amount of $35 million with a fixed interest rate of 1.4975% that we
designated as a cash flow hedge. The interest rate swap became effective on
January 15, 2020 and is scheduled to mature on September 16, 2024. If the
one-month LIBOR is above 1.4975%, the counterparty pays us, and if the one-month
LIBOR is less than 1.4975%, we pay the counterparty, the difference between the
fixed rate of 1.4975% and one-month LIBOR.

During the third quarter of 2019, we entered into an interest rate swap
agreement on a total notional amount of $50 million with a fixed interest rate
of a 1.144%. that we designated as a cash flow hedge. The interest rate swap
became effective on September 16, 2019 and is scheduled to mature on September
16, 2024. If the one-month LIBOR is above 1.144%, the counterparty pays us, and
if the one-month LIBOR is less than 1.144%, we pay the counterparty, the
difference between the fixed rate of 1.144% and one-month LIBOR.

We measure our interest rate swaps at fair value on a recurring basis. The fair
value of our interest rate swaps is based on quotes from third parties.  We
consider those inputs to be "level 2" in the fair value hierarchy as outlined in
the authoritative guidance for disclosures in connection with derivative
instruments and hedging activities. At December 31, 2020, the fair value of our
interest rate swaps was a net asset of $1.1 million which is included in
deferred charges and other assets on the accompanying consolidated balance
sheet. During the twelve months of 2021, we paid or accrued approximately $1.3
million in net payments made to the counterparty by us, adjusted for accruals,
pursuant to the terms of the swaps. From inception of the swap agreements
through December 31, 2021 we paid or accrued approximately $1.9 million in net
payments made to the counterparty by us pursuant to the terms of the swap
(consisting of approximately $198,000 in payments or accruals made to us by the
counterparty, offset by approximately $2.1 million of payments due to the
counterparty from us). During the twelve months of 2020, we paid or accrued
approximately $733,000 in net payments made to the counterparty by us, adjusted
for accruals, pursuant to the terms of the swaps (consisting of approximately
$824,000 in payments, adjusted for accruals, or accruals made to the
counterparty by us, offset by approximately $91,000 of payments paid to us by
the counterparty). Cash flow hedges are accounted for by recording the fair
value of the derivative instrument on the balance sheet as either an asset or a
liability, with a corresponding amount recorded in accumulated other
comprehensive income ("AOCI") within shareholders' equity. Amounts are
classified from AOCI to the income statement in the period or periods the hedged
transaction affects earnings.

The sensitivity analysis related to our fixed and variable rate debt assumes
current market rates with all other variables held constant. As of December 31,
2021, the fair value and carrying-value of our debt is approximately $331.3
million and $329.1 million, respectively. As of that date, the fair value
exceeds the carrying-value by approximately $2.2 million.

The table below presents information about our financial instruments that are
sensitive to changes in interest rates. The interest rate swaps include the $50
million swap agreement entered into during the third quarter of 2019, the $35
million swap agreement entered into in January 2020 and the $55 million swap
agreement entered into in March, 2020. For debt obligations, the amounts of
which are as of December 31, 2021, the table presents principal cash flows and
related weighted average interest rates by contractual maturity dates.



                                       49
--------------------------------------------------------------------------------

                                                          Maturity Date, Year Ending December 31
(Dollars in thousands)            2022         2023         2024         2025         2026       Thereafter        Total
Long-term debt:
Fixed rate:
Debt(a)                         $ 12,197     $ 11,892     $ 13,550     $     939     $  601     $     17,973     $  57,152
Average interest rates               4.4 %        4.4 %        4.4 %         4.3 %      4.2 %            4.3 %         4.4 %
Variable rate:
Debt(b)                         $      -     $      -     $      -     $ 271,900     $    -     $          -     $ 271,900
Average interest rates                 -            -            -           1.4 %        -                -           1.4 %
Interest rate swaps:
Notional amount (c)             $      -     $      -     $ 85,000     $       -     $    -     $     55,000     $ 140,000
Interest rates                         -            -        1.320 %           -          -            0.565 %       1.070 %


(a) Consists of non-recourse mortgage notes payable.

(b) Includes $271.9 million of outstanding borrowings under the terms of our $375

million revolving credit agreement.

(c) Includes a $50.0 million interest rate swap that became effective on

September 16, 2019, and a $35 million interest rate swap that became

effective on January 15, 2020, both of which are scheduled to mature during

2024. Additionally, included is a $55 million interest rate swap that became

effective on March 25, 2020, which is scheduled to mature in 2027.



As calculated based upon our variable rate debt outstanding as of December 31,
2021 that is subject to interest rate fluctuations, and giving effect to the
above-mentioned interest rate swap, each 1% change in interest rates would
impact our net income by approximately $1.3 million.
ITEM  8. Financial Statements and Supplementary Data


Our Consolidated Balance Sheets, Consolidated Statements of Income,
Comprehensive Income, Changes in Equity and Cash Flows, together with the
reports of KPMG LLP, an independent registered public accounting firm, are
included elsewhere herein. Reference is made to the “Index to Financial
Statements and Schedule.”
ITEM 9. Changes in and Disagreements With Accountants on Accounting and

Financial Disclosure

None.

© Edgar Online, source Glimpses

[ad_2]

Source link

Trending Topics

Features

Download and distribute powerful vaccination QI resources for your community.

Sign up now to support health equity and sustainable health outcomes in your community.

MCED tests use a simple blood draw to screen for many kinds of cancer at once.

FYHN is a bridge connecting health information providers to BIPOC communities in a trusted environment.

Discover an honest look at our Medicare system.

ARC was launched to create a network of community clinicians to diversify and bring clinical trials to communities of color and other communities that have been underrepresented.

The single most important purpose of our healthcare system is to reduce patient risk for an acute event.

Related Posts
Cyclospora Outbreak Linked to Recalled Lettuce Sickens More Than 1,600 Across Five States
How NMQF Advances Minority Health Through Data, Research and Health Access
Early Cancer Detection Is Entering a New Era. Flint Is Helping Lead the Way.
Scroll to Top
Featured Articles
Cyclospora Outbreak Linked to Lettuce Sickens 1,600+ fyh.news
Cyclospora Outbreak Linked to Recalled Lettuce Sickens More Than 1,600 Across...
How NMQF Advances Minority Health Through Data, Research and Health Access
How NMQF Advances Minority Health Through Data, Research and Health Access
Early Cancer Detection Is Entering a New Era. Flint Is Helping Lead the Way.
Early Cancer Detection Is Entering a New Era. Flint Is Helping Lead the Way.
Why Your “Ozempic” May Not Be Ozempic: FDA Warnings Highlight Growing Risks of Unregulated GLP-1 Drugs
Why Your “Ozempic” May Not Be Ozempic: FDA Warnings Highlight Growing Risks o...
The Communities Most Burdened by Disease Should Be the First to Benefit from Artificial Intelligence
The Communities Most Burdened by Disease Should Be the First to Benefit from ...
Cancer Pain Care Access Gap Hits Black, Asian Patients
Black and Asian Cancer Patients Wait Longer for Pain Relief in New Study
Categories
AI
ATTR-CM
BIPOC News
Cancer
Clinical Trials
Covid19
Diseases of the Body
Environment
Health Data
Health Equity Events
Health Policy
Health Tips
Subscribe to our newsletter to receive our latest news​
All Stories
Cyclospora Outbreak Linked to Lettuce Sickens 1,600+ fyh.news
Cyclospora Outbreak Linked to Recalled Lettuce Sickens More Than 1,600 Across...
How NMQF Advances Minority Health Through Data, Research and Health Access
How NMQF Advances Minority Health Through Data, Research and Health Access
Early Cancer Detection Is Entering a New Era. Flint Is Helping Lead the Way.
Early Cancer Detection Is Entering a New Era. Flint Is Helping Lead the Way.
BIPOC News
How NMQF Advances Minority Health Through Data, Research and Health Access
How NMQF Advances Minority Health Through Data, Research and Health Access
Early Cancer Detection Is Entering a New Era. Flint Is Helping Lead the Way.
Early Cancer Detection Is Entering a New Era. Flint Is Helping Lead the Way.
The Communities Most Burdened by Disease Should Be the First to Benefit from Artificial Intelligence
The Communities Most Burdened by Disease Should Be the First to Benefit from ...
Environment
UV Safety Awareness Month Raises Urgency on Skin Cancer Prevention and Sun Protection Equity
UV Safety Awareness Month Raises Urgency on Skin Cancer Prevention and Sun Pr...
Extreme Heat Safety Tips 5 Ways to Protect Your Health This Summer fyh.news
5 Heat Safety Tips That Could Protect Your Health This Summer
Lupus Awareness Event in Baltimore Aims to Support Research and Shine a Light on Health Disparities
Lupus Awareness Event in Baltimore Aims to Support Research and Shine a Light...
Work Force
A multigenerational Black and Hispanic family sitting together in a park, showing how Social Security helps support older adults, people with disabilities, and families across generations.
Millions of Older Americans Could Face Smaller Social Security Checks by 2032...
dreamstime_s_243253251
The Caregiver Journey: The Hidden Backbone of American Healthcare
Families gather at a Bronx community festival with live music, kids’ activities, and health booths sharing SOMOS social care resources and free screenings.
Celebrating Hispanic heritage while learning about health care

[xyz-ips snippet=”Output-Source-Name”]

Clinical Trials
Early Cancer Detection Is Entering a New Era. Flint Is Helping Lead the Way.
Early Cancer Detection Is Entering a New Era. Flint Is Helping Lead the Way.
Why Your “Ozempic” May Not Be Ozempic: FDA Warnings Highlight Growing Risks of Unregulated GLP-1 Drugs
Why Your “Ozempic” May Not Be Ozempic: FDA Warnings Highlight Growing Risks o...
Clinical Trial Diversity Remains a Critical Challenge in Alzheimer’s Research
Clinical Trial Diversity Remains a Critical Challenge in Alzheimer’s Research
Vaccines and Outbreaks
Cyclospora Outbreak Linked to Lettuce Sickens 1,600+ fyh.news
Cyclospora Outbreak Linked to Recalled Lettuce Sickens More Than 1,600 Across...
A parent checking a child's temperature during summer, illustrating the changing RSV patterns and year-round respiratory virus risks.
Can You Get RSV During the Summer?
Michelle Lam, MBA, of NYC Health + Hospitals/Elmhurst & Amy Harris of NYC Health + Hospitals/Elmhurst
Healthcare Leaders Spotlight Vaccine Equity and Adult Immunization Strategies...
Other Categories
AI
Read the latest AI News stories trending around the world
ATTR-CM
Cancer
Read the latest Cancer stories trending around the world
Covid19
Diseases of the Body
Read about the latest Diseases of the Body trending around the world
Friday Webinars
Every Friday, we bring you insightful webinars covering critical topics in healthcare, data equity, and policy reform.
Health Data
Read the latest Health Data stories trending around the world
Health Equity Events
Read the best Health Equity Events around the country.
Health Policy
Read the latest Health Policy stories trending around the world
Health Tips
Heart Health
Read the latest on Heart Health News, Stories and Tips.
kidney Health
Read more trending News about Kidney Health, Stories and Tips.